These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 9339268)
41. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Cummings JL; Schneider L; Tariot PN; Kershaw PR; Yuan W Am J Psychiatry; 2004 Mar; 161(3):532-8. PubMed ID: 14992980 [TBL] [Abstract][Full Text] [Related]
42. M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update. Fisher A; Heldman E; Gurwitz D; Haring R; Karton Y; Meshulam H; Pittel Z; Marciano D; Brandeis R; Sadot E; Barg Y; Pinkas-Kramarski R; Vogel Z; Ginzburg I; Treves TA; Verchovsky R; Klimowsky S; Korczyn AD Ann N Y Acad Sci; 1996 Jan; 777():189-96. PubMed ID: 8624083 [TBL] [Abstract][Full Text] [Related]
43. Current Findings and Potential Mechanisms of KarXT (Xanomeline-Trospium) in Schizophrenia Treatment. Azargoonjahromi A Clin Drug Investig; 2024 Jul; 44(7):471-493. PubMed ID: 38904739 [TBL] [Abstract][Full Text] [Related]
44. [Effectiveness of amiridin in senile dementia of the Alzheimer type]. Bukatina EE; Grigor'eva IV; Sokol'nik EI Zh Nevropatol Psikhiatr Im S S Korsakova; 1991; 91(9):53-8. PubMed ID: 1664616 [TBL] [Abstract][Full Text] [Related]
45. Design and development of selective muscarinic agonists for the treatment of Alzheimer's disease: characterization of tetrahydropyrimidine derivatives and development of new approaches for improved affinity and selectivity for M1 receptors. Messer WS; Rajeswaran WG; Cao Y; Zhang HJ; el-Assadi AA; Dockery C; Liske J; O'Brien J; Williams FE; Huang XP; Wroblewski ME; Nagy PI; Peseckis SM Pharm Acta Helv; 2000 Mar; 74(2-3):135-40. PubMed ID: 10812950 [TBL] [Abstract][Full Text] [Related]
46. Classics in Chemical Neuroscience: Xanomeline. Bender AM; Jones CK; Lindsley CW ACS Chem Neurosci; 2017 Mar; 8(3):435-443. PubMed ID: 28141924 [TBL] [Abstract][Full Text] [Related]
47. Effects of phosphatidylserine in Alzheimer's disease. Crook T; Petrie W; Wells C; Massari DC Psychopharmacol Bull; 1992; 28(1):61-6. PubMed ID: 1609044 [TBL] [Abstract][Full Text] [Related]
48. Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey. Vardigan JD; Cannon CE; Puri V; Dancho M; Koser A; Wittmann M; Kuduk SD; Renger JJ; Uslaner JM Psychopharmacology (Berl); 2015 Jun; 232(11):1859-66. PubMed ID: 25491927 [TBL] [Abstract][Full Text] [Related]
49. Evidence of trospium's ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results. Breier A; Brannan SK; Paul SM; Miller AC Psychopharmacology (Berl); 2023 May; 240(5):1191-1198. PubMed ID: 37036495 [TBL] [Abstract][Full Text] [Related]
50. Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study. Gutzmann H; Hadler D J Neural Transm Suppl; 1998; 54():301-10. PubMed ID: 9850939 [TBL] [Abstract][Full Text] [Related]
51. Changes in neuropsychiatric symptoms as outcome measures in clinical trials with cholinergic therapies for Alzheimer disease. Cummings JL Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S1-9. PubMed ID: 9339266 [TBL] [Abstract][Full Text] [Related]
52. The use of the Computerized Neuropsychological Test Battery (CNTB) in an efficacy and safety trial of BMY 21,502 in Alzheimer's disease. Cutler NR; Shrotriya RC; Sramek JJ; Veroff AE; Seifert RD; Reich LA; Hironaka DY Ann N Y Acad Sci; 1993 Sep; 695():332-6. PubMed ID: 8239308 [TBL] [Abstract][Full Text] [Related]
53. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia. Street JS; Clark WS; Kadam DL; Mitan SJ; Juliar BE; Feldman PD; Breier A Int J Geriatr Psychiatry; 2001 Dec; 16 Suppl 1():S62-70. PubMed ID: 11748789 [TBL] [Abstract][Full Text] [Related]
54. A bridging study of LU 25-109 in patients with probable Alzheimer's disease. Sramek JJ; Forrest M; Mengel H; Jhee SS; Hourani J; Cutler NR Life Sci; 1998; 62(3):195-202. PubMed ID: 9488097 [TBL] [Abstract][Full Text] [Related]